Secondary resection is a chance of cure for a subgroup of metastatic colorectal cancer (mCRC) patients with unresectable liver-limited disease. Medical treatment has a dual goal: to induce tumour shrinkage and to prevent disease relapse. The aims of the present analysis were to assess the efficacy of FOLFOXIRI plus bevacizumab in this setting, and to investigate whether this regimen could revert the poor prognosis of high-risk patients defined by clinical and molecular factors. We performed a pooled analysis of patients with unresectable and liver-limited mCRC, treated with first-line FOLFOXIRI plus bevacizumab in three prospective clinical trials by Gruppo Oncologico del Nord Ovest. 205 (37.9%) patients with liver-limited disease were sele...
Background/Aims: Conversion therapy can convert unresectable metastatic colorectal cancer (mCRC) int...
Background: A randomized phase III trial comparing the GONO-FOLFOXIRI regimen with FOLFIRI demonstra...
Background: Doublets plus bev are a standard option for the first-line treatment of mCRC. First-lin...
Secondary resection is a chance of cure for a subgroup of metastatic colorectal cancer (mCRC) patien...
OLIVIA, a multinational phase II study, suggests that bevacizumab plus FOLFOXIRI improves outcomes, ...
BACKGROUND: In patients with colorectal liver metastases (CLM) R0 resection significantly improves o...
BACKGROUND: In patients with colorectal liver metastases (CLM) R0 resection significantly improves ...
BACKGROUND: Preoperative treatment of resectable liver metastases from colorectal cancer (CRC) is a ...
Background: FOLFOXIRI plus bevacizumab is a valid option as upfront treatment for metastatic colorec...
BACKGROUND: In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) p...
Recently, in patients with unresectable colorectal liver metastasis, liver resection sometimes becom...
PURPOSE A proper estimation of the magnitude of the overall survival (OS) benefit from infusional fl...
BACKGROUND: In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan...
Background: Patients with initially unresectable colorectal cancer liver metastases might qualify fo...
Abstract: Retrospective studies reported that preoperative oxaliplatin-based chemotherapy increased ...
Background/Aims: Conversion therapy can convert unresectable metastatic colorectal cancer (mCRC) int...
Background: A randomized phase III trial comparing the GONO-FOLFOXIRI regimen with FOLFIRI demonstra...
Background: Doublets plus bev are a standard option for the first-line treatment of mCRC. First-lin...
Secondary resection is a chance of cure for a subgroup of metastatic colorectal cancer (mCRC) patien...
OLIVIA, a multinational phase II study, suggests that bevacizumab plus FOLFOXIRI improves outcomes, ...
BACKGROUND: In patients with colorectal liver metastases (CLM) R0 resection significantly improves o...
BACKGROUND: In patients with colorectal liver metastases (CLM) R0 resection significantly improves ...
BACKGROUND: Preoperative treatment of resectable liver metastases from colorectal cancer (CRC) is a ...
Background: FOLFOXIRI plus bevacizumab is a valid option as upfront treatment for metastatic colorec...
BACKGROUND: In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) p...
Recently, in patients with unresectable colorectal liver metastasis, liver resection sometimes becom...
PURPOSE A proper estimation of the magnitude of the overall survival (OS) benefit from infusional fl...
BACKGROUND: In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan...
Background: Patients with initially unresectable colorectal cancer liver metastases might qualify fo...
Abstract: Retrospective studies reported that preoperative oxaliplatin-based chemotherapy increased ...
Background/Aims: Conversion therapy can convert unresectable metastatic colorectal cancer (mCRC) int...
Background: A randomized phase III trial comparing the GONO-FOLFOXIRI regimen with FOLFIRI demonstra...
Background: Doublets plus bev are a standard option for the first-line treatment of mCRC. First-lin...